Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio

Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts

Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.

Roche_Basel
Lunsumio and the late-stage glofitamab will complement antibody drug conjugate Polivy in Roche's hemato-oncology portfolio. • Source: Shutterstock

Roche has gained conditional marketing authorisation for Lunsumio (mosunetuzumab) in the European Union, marking the first approval of a CD20xCD3 T-cell engaging bispecific antibody anywhere in the world.

The approval helps keep the company ahead of its rivals in the same class, most notably Genmab/AbbVie’s epcoritamab,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip